CiteFacts · FDA Drug Shortages · FDA source
Hydromorphone Hydrochloride Injection
Status
FDA currently lists this ingredient in shortage.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| Fresenius Kabi USA, LLC | Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06) | Unavailable | 08/04/2026 |
| Fresenius Kabi USA, LLC | Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11) | Unavailable | 08/04/2026 |
| Fresenius Kabi USA, LLC | Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11) | Unavailable | 08/04/2026 |
| Fresenius Kabi USA, LLC | Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15) | Unavailable | 08/04/2026 |
| Fresenius Kabi USA, LLC | Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10) | Available | 08/04/2026 |
| Hikma Pharmaceuticals USA, Inc. | Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25) | Available | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01) | Unavailable | 08/13/2026 |
| Hospira, Inc., a Pfizer Company | Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01) | Unavailable | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01) | Limited Availability | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37) | Unavailable | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50) | Available | 08/07/2026 |
| Teva Pharmaceuticals USA, Inc. | Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01) | Available | 08/17/2026 |
| Teva Pharmaceuticals USA, Inc. | Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03) | Available | 08/17/2026 |
| Teva Pharmaceuticals USA, Inc. | Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03) | Available | 08/17/2026 |
Source facts
Grouped generic ingredient: Hydromorphone Hydrochloride Injection · 26 package records · Latest FDA row update: 08/17/2026
Therapeutic categories: Analgesia/Addiction
Dosage forms: Injection
Routes: INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.